Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Misses Expectations By $0.05 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) posted its earnings results on Wednesday. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.05), Fidelity Earnings reports.

Shares of YMAB traded up $0.37 on Thursday, reaching $26.53. The company’s stock had a trading volume of 1,597 shares, compared to its average volume of 119,870. The company has a quick ratio of 13.30, a current ratio of 13.30 and a debt-to-equity ratio of 0.02. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $31.00. The firm has a market cap of $810.39 million and a PE ratio of -17.95. The company has a fifty day moving average of $22.95.

In related news, insider Thomas Gad sold 4,000 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $21.78, for a total value of $87,120.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders sold a total of 30,000 shares of company stock worth $646,500 in the last 90 days. 38.40% of the stock is currently owned by company insiders.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Saturday, August 3rd. HC Wainwright restated a “buy” rating and issued a $40.00 target price (up previously from $36.00) on shares of Y-mAbs Therapeutics in a report on Monday, June 10th. Finally, Cowen restated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $31.40.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: What is meant by a buy rating?

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit